Table 3.
2-hPG, FPG and HbAlc before and after the intervention across different groups
| Ta-VNS | Sham taVNS | No-treatment | |
|---|---|---|---|
|
2hPG Baseline |
9.7 (1.2) |
9.1(1.2) |
9.3 (1.1) |
|
2hPG 6-weeks |
7.3 (1.8)** |
8.0 (1.6)** |
9.5 (1.9) |
|
2hPG 12-weeks |
7.5 (1.3)** |
8.0 (1.4)** |
10.0 (2.7) |
|
FPG Baseline |
6.2 (0.6) |
6.3 (0.5) |
6.5 (0.3) |
|
FPG 6-weeks |
5.9 (0.8)** |
6.2 (0.8) |
6.6 (0.8) |
|
FPG 12-weeks |
5.7 (0.6)** |
6.2 (0.8) |
6.9 (1.2) |
|
HbAlc Baseline |
6.3 (0.5) |
6.2 (0.6) |
6.2 (0.4) |
|
HBAlc 12-weeks |
6.1 (0.4)* |
6.0 (0.4)* |
6.3 (0.6) |
|
BMI Baseline |
24.5 (3.5) |
23.9 (2.6) |
25.7 (3.4) |
| BMI 12-weeks | 24.1 (3.3) | 23.5 (2.6) | 25.4 (3.0) |
Compared to No-treatment group, *p < 0.05, **p < 0.01.
All values are presented as mean (SD).